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Objective: Several prosthetic materials have been used for femoropopliteal bypass grafting in patients with peripheral
vascular disease in whom a venous bypass is not possible. Expanded polytetrafluoroethylene (ePTFE) is the most
commonly used, but patency results have not always equaled those achieved with vein, especially in below-knee
reconstructions. This study assessed the performance of a new heparin-bonded ePTFE vascular graft that was designed to
provide resistance to thrombosis and thereby decrease early graft failures and possibly prolong patency.
Method: From June 2002 to June 2003, 86 patients (62 men and 24 women; mean age, 70 years; 99 diseased limbs) were
enrolled prospectively in a nonrandomized, multicenter study of the heparin-bonded ePTFE graft. Fifty-five above-knee
and 44 below-knee (including 21 femorocrural) procedures were performed. Follow-up evaluations consisted of clinical
examinations, ultrasonographic studies, and distal pulse assessments. Patency and limb salvage rates were assessed by
using life-table analyses.
Results: All grafts were patent immediately after implantation. There were no graft infections or episodes of prolonged
anastomotic bleeding. During the 1-year follow-up, 10 patients died, 15 grafts occluded, and 5 major amputations were
performed. The overall primary and secondary 1-year patency rates were 82% and 97%, respectively. The limb salvage rate
in patients with critical limb ischemia (n  41) was 87%. Primary patency rates according to bypass type were 84%, 81%,
and 74% for above-knee femoropopliteal, below-knee femoropopliteal, and femorocrural bypasses, respectively; the
corresponding secondary patency rates were 96%, 100%, and 100%.
Conclusions: In this study, the heparin-bonded ePTFE graft provided promising early patency and limb salvage results,
with no device-related complications, in patients with occlusive vascular disease. Longer-term and randomized studies are
warranted to determine whether this graft provides results superior to those achieved with other prostheses, especially in
patients at increased risk of early graft failure, such as those undergoing below-knee bypass and those with poor run-off
or advanced vascular disease. ( J Vasc Surg 2006;43:313-9.)Patients with severe peripheral arterial occlusive disease
may require bypass surgery to relieve symptoms, restore
their ability to walk, or avoid foot amputation. Autologous
saphenous vein is generally the preferred conduit,1 although,
in above-knee (AK) femoropopliteal (FP) reconstructions,
expanded polytetrafluoroethylene (ePTFE) grafts may yield
patency results comparable to those achieved with vein, par-
ticularly in the short term.2-5 In contrast, the results for
below-knee (BK) procedures using a small-diameter pros-
thesis (6 mm) have been disappointing. Nevertheless,
many patients cannot undergo autologous vein bypass
grafting because no suitable vein is available or because they
are at increased risk of wound complications or infections
associated with vein harvesting. Thus, much current re-
search is focused on improving the patency of prosthetic
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Prosthetic graft occlusion has several related causes,
including technical failure at implantation, progression of
vascular disease, intimal hyperplasia at the anastomosis
between the graft and vessel, and thrombosis.6,7 Thrombus
deposition on the graft lumen appears to be the primary
cause of early graft occlusion, especially in small-caliber
prostheses.6-9 For FP bypasses, the rate of graft failure is
highest in the first months after surgery.2,10-12 Therefore,
under the assumption that improving the thromoboresis-
tance of prosthetic grafts would decrease early failures and
thereby improve patency results, researchers began to in-
vestigate the effects of attaching heparin, an anticoagulant
agent with a long history of safety and efficacy, to these
grafts.
The use of heparin coatings on several types of medical
devices, including extracorporeal circuits for cardiopulmo-
nary bypass13,14 and stents,15 has successfully enhanced
hemocompatibility and improved patient outcome. The
optimal method for attaching heparin to a prosthetic sur-
face must provide long-term retention of the agent on that
surface as well as sustained heparin activity.6 Several attach-
ment techniques have been developed, but one of the most
common and successful is the Carmeda BioActive Surface
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uses covalent end-point linkage to retain heparin on the
device surface.15-18 Experimental use of a CBAS-bonded
ePTFE graft for vascular bypass in dogs6,7 and baboons8
has been reported. The findings of these studies with re-
spect to sustained heparin activity, reduction in platelet
deposition, inhibition of anastomotic intimal hyperplasia,
and graft patency were encouraging.
A CBAS-ePTFE graft (GORE-TEX PROPATEN Vas-
cular Graft; W. L. Gore & Assoc, Flagstaff, Ariz) has been
available for clinical use in Europe since 2002. In 2002, we
began to use the CBAS-ePTFE graft in patients requiring a
prosthetic FP bypass procedure in a multicenter, prospec-
tive, nonrandomized study. We here describe our 1-year
follow-up results with this device. To our knowledge, this is
the first reported clinical series of FP bypass procedures
using the CBAS-ePTFE prosthesis.
METHODS
Patients. Approval for the study was obtained from
the authors’ local institutional review boards, and the in-
vestigation was conducted in accordance with the principles
outlined in the Declaration of Helsinki. All enrolled pa-
tients provided informed consent to participate.
The enrollment period was June 2002 to June 2003.
Patients referred for surgery were included in the study if
they required a prosthetic AK FP, BK FP, or femorocrural
(FC) bypass because of occlusive vascular disease (Ruther-
ford class 3). Patients with a known sensitivity to hep-
arin on platelet count assessments, a previous bypass
operation in the same extremity, or an active infection at
either planned incision site were excluded from the
study, as were patients requiring complex concomitant
procedures, such as sequential or composite revasculariza-
tion of the extremity.
Standard surgical bypass techniques were used; no spe-
cial implantation or handling methods were used. All grafts
were straight, thin-walled, and 6 mm in diameter, and all
had an external ring support system. Neither patches nor
cuffs were used in end-to-side anastomoses. In all cases,
angiography was performed immediately after graft implan-
tation to detect technical failures. Intraoperative antiplate-
let or anticoagulant therapy, including administration of
heparin, was given in accordance with the standards of care
at the participating centers. Postoperatively, patients re-
ceived clopidogrel (75 mg/day) for the first month after
surgery, low-molecular-weight heparin (0.6 mL/day) for
the first 3 weeks (following the institution’s standard post-
operative protocol), and aspirin (100 mg/day) indefinitely.
Follow-up protocol. Postoperative follow-up visits
occurred approximately 1 month, 6 months, and 1 year
after surgery. At each visit, a clinical examination was
performed, as well as a color-flow duplex ultrasonographic
study to detect stenosis in the bypass graft or native artery,
and measurement of distal pulses.
Data analysis. Before surgery, information was col-
lected on the patients’ demographic characteristics, risk
factors for vascular disease, Rutherford disease-stage classi-fication, and distal pulses. Intraoperative and postoperative
procedure-related and disease-related adverse events, in-
cluding death, anastomotic or other bleeding, wound or
graft infection, stroke, myocardial infarction, and perigraft
hematoma and seroma were recorded, as were any graft
occlusions and revascularization procedures. Patient sur-
vival, primary graft patency, secondary graft patency, and
limb salvage data were assessed by using life-table or
log-rank analyses. Differences resulting in P .05 were
considered significant.
Primary graft patency was defined as blood flow
through a graft for which there had been either no reinter-
vention to restore flow or reintervention only for an occlu-
sion or stenosis in a distal or proximal native vessel. Second-
ary patency was defined as blood flow through a graft that
required reintervention to restore flow. Limb salvage was
defined as prevention of any major amputation (ie, above-
heel amputation) in patients with critical limb ischemia
(CLI).
RESULTS
Patients and follow-up compliance. The study en-
rolled 86 patients, and their demographic data, vascular
disease risk factors, preoperative Rutherford class of af-
fected limbs, and preoperative run-off information are sum-
Table I. Patient characteristics
Characteristic Value*
Mean age (y) (range) (N  86 patients) 70 (45-89)
Male/Female 62 (72)/24 (28)
Risk factors
Previous peripheral vascular disease
treatment
66 (77)
Coronary artery disease 34 (40)
Cerebrovascular disease 15 (17)
Renal insufficiency 8 (9)
Obesity 6 (7)
Diabetes mellitus 24 (28)
Hypertension 62 (72)
Hypercholesterolemia 38 (44)
Nicotine use 39 (45)
Preoperative Rutherford class




Preoperative run off (N  100 limbs)‡
No patent artery 7 (7)
1 patent artery 51 (51)
2 patent arteries 21 (21)
3 patent arteries 21 (21)
*Values are number (percentage) unless otherwise indicated.
†38 above-knee (AK) femoropopliteal (FP), 12 below-knee (BK) FP, and 8
femorocrural (FC) procedures in Rutherford class 3 limbs; 8 AK FP, 5 BK
FP, and 3 FC in class 4 limbs; and 9 AK FP, 7 BK FP, and 10 FC in class 5
limbs. A limb in which a revision bypass was performed was subsequently
excluded from the study.
‡Number of arteries with outflow from the area of the proposed vascular
bypass. A limb in which a revision bypass was performed was subsequently
excluded from the study.marized in Table I. None of the patients had concomitant
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and one patient had a BK bypass in both legs and a revision
bypass in the right leg. The revision bypass was excluded
from the series; therefore, 99 infrainguinal bypasses were
performed during the enrollment period: 55 AK and 44 BK
procedures, with 21 of the BK bypasses having a crural
anastomosis (Table II). Of the study patients who survived,
94% returned for their 1-month follow-up visit, 92% for
their 6-month visit, and 95% for their 1-year visit.
Adverse events. Information on deaths and amputa-
tions in the series is given in Table II. Ten of the 86 patients
died during the 1-year postoperative follow-up period, 3
within the first month after the bypass procedure (30-day
mortality rate, 3%), 2 between 1 and 3 months, 3 between
3 and 6 months, and 2 between 6 and 12 months. Seven of
the 10 patients who died were aged 70 years old, and no
patient aged 60 died. Five deaths occurred among the 46
patients withRutherford class 3 disease and five among the 26
patients with Rutherford class 5 disease (P.05). In one of
the 10 patients who died, the CBAS-ePTFE graft was
found to have occluded during a previous follow-up visit.
No perioperative (30 days) complications occurred in
the series. Five major amputations were necessary during
the 1-year follow-up period (Table II). No patient with a
patent graft required amputation; all amputations were of
limbs with graft thrombosis. All patients who underwent
amputation had chronic CLI (Rutherford class 4 or 5)
preoperatively. On life-table analysis, the 1-year limb sal-
vage rate for the 41 limbs with CLI before surgery was 87%
Table II. Bypass type and postoperative adverse events
Result No. (%)
Distal anastomosis (N  100 total procedures)
AKFP 55 (55)
FP 1* 46 (46)
FP 2* 7 (7)
BK 45 (45)
FP 3* 24 (24)
Femoral-anterior tibial artery† 5 (5)
Femoral-tibioperoneal trunk† 8 (8)
Femoral-posterior tibial artery† 3 (3)
Femoral-peroneal artery† 5 (5)
Adverse events according to procedure type
Deaths (N  86 patients) 10 (12)
Patients who had AK FP 4 (5)
Patients who had BK FP 3 (3)
Patients who had FC 3 (3)
Major amputations (N  99 limbs)‡ 5 (5)
Limbs with AK FP 1 (1)
Limbs with BK FP 2 (2)
Limbs with FC 2 (2)
AK, Above-knee; FP, femoropopliteal; BK, below-knee; FC, femorocrural.
*N  77 FP anastomoses with the anastomosis located between Hunter’s
canal and the top of the patella (FP 1), the top of the patella and the knee
articulation (FP 2), or distal of the knee articulation (FP 3).
†N  21 FC anastomoses.
‡A limb in which a revision bypass was performed was subsequently excluded
from the study.(Fig 1). No patients in the series had infections or perigraftseromas, prolonged anastomotic bleeding, or heparin-
induced thrombocytopenia (HIT).
Patency. During the first year after surgery, 15 of the
99 grafts implanted occluded: 2 within the first month, 8
between 1 and 6 months, and 6 between 6 and 12 months.
All occlusions were treated with thrombolysis and percuta-
neous transluminal angioplasty. Life-table data for overall
primary and secondary patency of the CBAS-ePTFE grafts
at 1 year are shown in Fig 2. The overall 1-year primary and
secondary patency rates were 82% (95% confidence interval
[CI], 73% to 90%) and 97% (95% CI, 94% to 100%),
Fig 1. Life-table analysis of limb salvage among the 41 patients
(limbs) in the series with chronic critical limb ischemia (CLI). The
values below the x-axis represent the numbers of limbs at risk at the
start of the study and at the start of the intervals 0 to 1 month, 1 to
6 months, and 6 to 12 months.
Fig 2. Life-table analysis of overall 1-year primary and secondary
patency of Carmeda BioActive Surface expanded polytetrafluoro-
ethylene (CBAS-ePTFE) grafts. The values below the x-axis rep-
resent the numbers of limbs at risk at the start of the study and at
the start of the intervals 0 to 1 month, 1 to 6 months, and 6 to 12
months.respectively.
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patency of the CBAS-ePTFE grafts according to bypass
type are shown in Fig. 3. The 1-year primary patency rates
were 84% for AK FP, 81% for BK FP, and 74% for FC
bypasses. The 1-year secondary patency rates were 96% for
AK FP, 100% for BK FP, and 100% for FC bypasses.
As expected, occlusion of CBAS-ePTFE grafts took
place more frequently in patients with more extensive dis-
ease and fewer run-off vessels. Thus, the 1-year primary
patency rates were 89% for limbs with Rutherford class 3
disease, 79% for class 4 limbs, and 68% for class 5 limbs;
however, the differences in patency among the three classes
were not significant (P .06 on log-rank testing). The
1-year primary patency rate for limbs with an isolated
popliteal segment or only one outflow artery was 72%,
whereas that for limbs with two or three run-off arteries was
95% (P .004 on log-rank testing) (Fig. 4).
DISCUSSION
In this first reported clinical series of infrainguinal by-
passes using a new heparin-bonded ePTFE graft, the
CBAS-ePTFE prosthesis was found to be safe to use, and
the graft yielded 1-year patency and limb salvage rates
comparable with or superior to those obtained with other
prostheses. Our results for small-diameter infragenicular
bypasses, which have historically had poor patency, were
especially encouraging. The mortality rate (12%) may ap-
pear somewhat high, but was probably due to the age of the
Fig 3. Life-table analysis of 1-year primary patency of Carmeda
BioActive Surface expanded polytetrafluoroethylene (CBAS-ePTFE)
grafts according to bypass type. The 6-month and 1-year primary
patency rates for the FC bypasses were both 74%, but this is not
shown on the graft because the standard error was greater than 10%
(11.3%). The values below the x-axis represent the numbers of
limbs at risk at the start of the study and at the start of the following
intervals: 0 to 1 month, 1 to 6 months, and 6 to 12 months. AK
FP, Above-knee femoropopliteal; BK FP, below-knee femoropop-
liteal; FC, femorocrural.patients and their overall health status. Seven of the deathsoccurred in patients aged 70 years, and seven patients
died of myocardial infarction. Five of the patients who died
had Rutherford class 5 vascular disease, and the 1-year
mortality rate among such patients, with or without recon-
struction, has been observed to be 26%.19
Medical devices with a heparin attachment have been
available for several years. As Kocsis et al15 noted, heparin is
applied to artificial surfaces with the aim of controlling
formation of the initial fibrin and platelet layers. Because
heparin is negatively charged, it may be attached to an
artificial surface ionically, but this type of attachment is
unstable and results in rapid release of the heparin from
the surface.15 Conventional covalent bonding necessitates
multiple attachment points along the length of the heparin
molecule to facilitate surface attachment. Although this
attachment technique immobilizes the heparin, preventing
its release, it also compromises the ability of heparin to bind
antithrombin III.
The CBAS technology circumvents this problem by
using a single end-point covalent bond to immobilize the
heparin molecule. This allows the immobilized heparin to
bind antithrombin and therefore retain its anticoagulant
properties on the graft surface.6-8 The heparin-binding
process occurs at the nanometer level; therefore, CBAS-
ePTFE grafts retain the 30-m internodal distance and
porosity of standard, nonheparinized ePTFE vascular
grafts. Because themicrostructure of CBAS-ePTFE grafts is
essentially the same as that of standard ePTFE grafts, they
have the same elasticity and handling characteristics of the
standard prostheses.
In vivo studies of small-diameter CBAS-ePTFE grafts
have been conducted in dogs6,7 and baboons.8 In a canine
model in which 3-mm-diameter CBAS-ePTFE grafts were
implanted in the carotid arteries, Begovac et al6 measured
Fig 4. Life-table analysis of 1-year primary patency of Carmeda
BioActive Surface expanded polytetrafluoroethylene (CBAS-ePTFE)
grafts according to the number of patent outflow vessels before
graft implantation. The values below the x-axis represent the
numbers of limbs at risk at the start of the study and at the start of
the intervals 0 to 1 month, 1 to 6 months, and 6 to 12 months.thrombus deposition, assessed patency up to 180 days, and
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surface to bind antithrombin. The heparin-bonded grafts
were found to have a significantly greater area of thrombus-
free luminal surface and significantly better patency than
control ePTFE grafts (no CBAS binding). Heparin activity,
as indicated by antithrombin III binding assessments, was
measurable on the CBAS-ePTFE grafts throughout the
12-week observation period. The ability of heparin to bind
antithrombin III is central to its anticoagulant function.
In the canine study conducted by Lin et al,7 4-mm
CBAS-ePTFE and non-CBAS-ePTFE grafts were used in
femorofemoral bypass grafting. The CBAS grafts had sig-
nificantly less platelet deposition 24 hours after implanta-
tion and significantly greater inhibition of anastomotic
intimal hyperplasia. At 4 weeks, patency rates were 89% for
the CBAS-ePTFE grafts and 44% for control ePTFE pros-
theses. The study in baboons8 used 4-mm-diameter CBAS-
ePTFE grafts and control grafts in aortoiliac reconstruc-
tions. Compared with control grafts, the heparin-coated
grafts had significantly less intimal hyperplasia and platelet
deposition.
In the light of these in vivo results, we speculate that a
decrease in platelet and thrombus deposition on the CBAS-
ePTFE graft surface may have contributed to the promising
1-year patency rates in our clinical series. Although amelio-
ration of intimal hyperplasia is not the primary target of
heparinization technology, it is intriguing to consider the
possibility that the CBAS graft surface might simulta-
neously address two sources of graft failure: thrombosis and
intimal hyperplasia.
Clinical use of a heparin-bonded (non-CBAS) polyester
graft in FP bypass grafting has been reported.10,11 In a 209-
patient randomized study comparing this graft with a non-
heparinized ePTFE graft, the performance of the heparin-
bonded graft was significantly better, with an overall 1-year
patency rate of 70% and rates of 75% and 38%, respectively,
for AK and BK FP bypasses. The overall 1-year secondary
patency rate was 74%, and the 1-year limb salvage rate was
96%.10 Our results with the CBAS-ePTFE graft appear to
be superior to those obtained with the heparin-bonded
Dacron graft, although only a randomized study can deter-
mine whether the CBAS-ePTFE prosthesis will consistently
yield better outcomes.
In vitro studies showed that heparin was present on the
polyester graft for up to 4 weeks, although heparin activity
was not measured.20 In contrast, in vivo studies observed
heparin activity on the surface of CBAS-ePTFE grafts for
12 weeks.6 The sustained heparin activity offered by the
CBAS-ePTFE prosthesis may explain its apparently better
clinical performance. It is also worth noting that small-
diameter polyester grafts have a history of thrombogenicity
and are therefore seldom used in infrainguinal bypasses.11,21
On the other hand, the promising results achieved with the
heparin-bonded polyester prosthesis provide additional ev-
idence that attachment of heparin to a bypass graft repre-
sents an advance in technology that may improve the
quality of life of patients with severe vascular disease.Heparin-induced thrombocytopenia is a rare but po-
tentially serious condition that has been observed in pa-
tients given heparin therapy for several days. There are a few
reports of heparin-releasing implantable medical devices
contributing to HIT but, to our knowledge, only one
report of HIT type II development in a patient given a
heparin-bonded device (a coronary artery stent).22,23 It
remains unknown whether the heparin on the stent actually
contributed to the HIT. The patient was treated without
removal of the device and the condition resolved. We have
found no reports associating HIT type II with a CBAS-
ePTFE vascular graft. In our series, patients were screened
preoperatively forHIT bymeans of platelet counts because,
according to the instructions for use of the CBAS-ePTFE
graft, the prosthesis is contraindicated in those with a
known sensitivity to heparin. We did not routinely conduct
serial platelet counts after graft implantation, but no clinical
or other evidence of HIT was observed in any patient.
An unexpected finding of our study was that the CBAS-
ePTFE graft provided extremely good results in sub-
groups of patients who either underwent infragenicular
bypass or had poor preprocedure vessel run-off. We believe
that this prosthesis offers an important benefit over nonhe-
parin-coated grafts in these patient populations, although a
prospective randomized trial is needed to confirm this
impression.
A 2003 meta-analysis of about 40 studies of nonheparin-
coated ePTFE graft bypasses to the infrapopliteal arteries24
yielded pooled 1-year primary and secondary patency rates
of 59% (95% CI, 53% to 64%) and 66% (95% CI, 60% to
73%), respectively. The calculated foot-preservation rate at
1 year for all grafts was 78% (95% CI, 72% to 84%). A recent
systematic review of large studies of AK popliteal bypasses1
did not report 1-year patency rates, but the pooled 2-year
rates for ePTFE grafts were 67% for primary patency and
75% for secondary patency. For BK bypasses, approximate
rates for 1-year primary patency of 40% to 60% and limb
salvage of 60% to 80% have been reported.11,12,25 In the
current study, the overall primary and secondary 1-year
patency rates for the CBAS-ePTFE graft were 82% and
97%, respectively. The limb salvage rate in patients with
CLI was 87%. The 1-year primary patency rates according
to bypass type were 84%, 81%, and 74% for AK FP, BK FP,
and FC bypasses, respectively; the corresponding secondary
patency rates were 96%, 100%, and 100%. Thus, our results,
especially in BK bypass grafting, appear to be better than
those achieved with prosthetic grafts lacking heparin.
Longer-term and randomized studies of the CBAS-
ePTFE graft in FP bypass grafting are warranted to provide
more definitive information about the graft’s patency and
limb salvage performance. Our findings, however, indicate
that use of this graft is an excellent option for infrainguinal
bypass grafting in patients with peripheral vascular disease
when autologous vein is not available. In addition, the
CBAS-ePTFE graft may represent a viable alternative for
BK bypasses, which have traditionally yielded less than
desirable outcomes.
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Bosiers et al herein report the first clinical series of infraingui-
nal bypass with a new, heparin-bonded, expanded polytetrafluoro-
ethylene (ePTFE) prosthesis. This option has now been added tochoose when performing infrainguinal bypass. The menu includes
reversed, nonreversed, and in situ great and short saphenous vein;
alternate (arm) vein; Dacron; heparin-bonded Dacron; human
umbilical vein (HUV); Distaflo (Bard Peripheral Vascular, Inc,
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Volume 43, Number 2 Mills 319Tempe, Ariz) ePTFE; and standard ePTFE, to which one may add
adjuncts such as a Miller cuff, St. Mary’s collar, Taylor patch, or
distal arteriovenous fistula.
Although this report is interesting and provocative, it repre-
sents at most a tantalizing tidbit on the smorgasbord of vascular
grafts rather than a substantial main course. The study was con-
ducted in a relatively low-risk group of patients and was limited by
small sample size, short follow-up, and lack of a control group.
Fifty-five of the 99 procedures were above-knee (AK) femoropop-
liteal (FP) bypasses, and 58 of the procedures were performed for
claudication (Rutherford grade I, category 3); only 16 procedures
were performed in patients with rest pain (grade II, category 4),
and 26 bypasses were performed in individuals with minor tissue
loss (category 5). Among 45 infrageniculate bypasses, the insertion
site was the below-knee (BK) popliteal artery in 24 patients and a
crural vessel in 21.
Ten of 86 patients died during the first follow-up year, and 15
of 99 implanted grafts occluded during the first year after surgery,
leaving small numbers of patients and grafts available for even
short, 1-year follow-up. Reported, 1-year life-table primary pa-
tency rates were 84% for AK FP bypasses and 81% for BK FP grafts.
The numbers were so small for the crural subgroup that the
standard of error was 10% at both 6 and 12 months, making the
Kaplan-Meier curve unreliable.
Skeptics will note that almost any material performs well for
the first 1 to 3 years in claudicants with an AK popliteal insertion
site. At least three prospective, randomized trials have demon-
strated equivalence between ePTFE and Dacron for AK FP bypass.
Although a single study of 209 patients reported early improve-ment in FP graft patency for heparin-bonded Dacron compared
with standard ePTFE at 3 years, by 5 years, results were equivalent.
Randomized prospective trials have demonstrated that vein out-
performs all prosthetic conduits for all infrainguinal insertion sites;
while the demonstration of vein superiority in the AK position
requires 3 to 5 years of follow-up, the superiority of vein over
prosthetic has been readily demonstrated for BK FP and femoro-
crural bypasses with only 1 to 2 years of follow-up. A single study
of PTFE with a Miller cuff for BK popliteal bypass reported
dramatically improved 2-year patency (52% vs 29%) associated with
the addition of a distal cuff.
If the vascular surgeon of 2005 were to approach the infrain-
guinal graft smorgasbord and find that vein is unavailable, what
conduit should he select? The present study will not help him reach
a decision. Available in vitro animal studies suggest that heparin is
detectable for up to 4 weeks on polyester Dacron grafts. Heparin
activity has been reported to be measurable for up to 12 weeks on
heparin-bonded ePTFE grafts. Whether this possibly longer dura-
tion of heparin activity confers increased thromboresistance as well
as a patency advantage for heparin-bonded ePTFE grafts is uncer-
tain. The clinical utility of this potentially promising off-the-shelf
prosthesis will require prospective, randomized trials. Suitable
control groups would include standard ePTFE, PTFE with a distal
venous adjunct (cuff, collar, or patch), and perhaps ePTFE with a
modified distal cuff such as Distaflo. Given the apparent aversion of
vascular surgeons to prospective, randomized trials of infrainguinal
bypass grafts, we may have to wait for quite a while before we
know. Until then, the conduit choice in the absence of suitable
vein remains a highly subjective matter of taste.
